RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Viking Therapeutics Stock

Viking Therapeutics Liabilities 2024

Viking Therapeutics Liabilities

20.07 M USD

Ticker

VKTX

ISIN

US92686J1060

WKN

A12GD6

In 2024, Viking Therapeutics's total liabilities amounted to 20.07 M USD, a -13.49% difference from the 23.2 M USD total liabilities in the previous year.

Viking Therapeutics Aktienanalyse

What does Viking Therapeutics do?

Viking Therapeutics Inc. is a biotechnology company specializing in the development of drugs for the treatment of metabolic and endocrine disorders. It was founded in 2012 by Brian Lian, Ph.D., and is headquartered in San Diego, California. The company's business model focuses on targeting liver X receptors (LXRs) for the treatment of metabolic disorders. Viking Therapeutics aims to develop treatment options for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as osteoporosis and hypothyroidism. Their lead products in development are VK2809 for NAFLD/NASH and VK5211 for osteoporosis. The company has a promising product pipeline and aims to improve the lives of millions of patients. Viking Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Viking Therapeutics's Liabilities

Viking Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Viking Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Viking Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Viking Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Viking Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Viking Therapeutics stock

What is the level of liabilities of Viking Therapeutics this year?

Viking Therapeutics has a debt balance of 20.07 M USD this year.

What were the liabilities of Viking Therapeutics compared to the previous year?

The liabilities of Viking Therapeutics have increased by -13.49% dropped compared to the previous year.

What are the consequences of high debt for investors of Viking Therapeutics?

High liabilities can pose a risk for investors of Viking Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Viking Therapeutics?

Low liabilities mean that Viking Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Viking Therapeutics affect the company?

An increase in liabilities of Viking Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Viking Therapeutics affect the company?

A decrease in the liabilities of Viking Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Viking Therapeutics?

Some factors that can influence the liabilities of Viking Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Viking Therapeutics so important for investors?

The liabilities of Viking Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Viking Therapeutics take to modify the liabilities?

To change its liabilities, Viking Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Viking Therapeutics pay?

Over the past 12 months, Viking Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Viking Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Viking Therapeutics?

The current dividend yield of Viking Therapeutics is .

When does Viking Therapeutics pay dividends?

Viking Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Viking Therapeutics?

Viking Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Viking Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Viking Therapeutics located?

Viking Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Viking Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Viking Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Viking Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Viking Therapeutics in the year 2023?

In the year 2023, Viking Therapeutics distributed 0 USD as dividends.

In which currency does Viking Therapeutics pay out the dividend?

The dividends of Viking Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Viking Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Viking Therapeutics

Our stock analysis for Viking Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Viking Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.